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Understanding the development and maintenance of dopamine neurons is essential to establish novel stem
cell therapies and animal models of Parkinson’s disease. A recent PLoS Biology report (Kittappa et al., 2007)
reveals that Foxa2 regulates dopamine neuron generation and differentiation, and that aging foxa2+/ mice
spontaneously develop Parkinsonism.Progress toward the formidable goal of
developing stem cell therapies must
overcome a series of developmental and
disease-specific challenges. When con-
sidering Parkinson’s disease (PD), the
list of hurdles includes determining the
processes responsible for the normal
birth and development of dopamine (DA)
neurons, the mechanism by which this
population is selectively lost in affected
individuals, and methods to generate,
transplant, integrate, and protect replace-
ment cells in treated patients. A recent
study from the McKay lab (Kittappa
et al., 2007) demonstrates that overex-
pression of the transcription factor Foxa2
promotes the generation of DA neurons
from mouse ES cells. Moreover, deletion
of one allele of foxa2 via gene targeting re-
sults in DA cell loss and yields an animal
model of Parkinsonism.
In this study, Kittappa and colleagues
used the sonic hedgehog (shh) promoter
to map the fates of both DA and oculomo-
tor neurons. They observed that the vast
majority of DA neurons were derived
from shh-expressing progenitors in the
floor plate. Previous reports have shown
that the shh-regulated gene foxa2 is
both sufficient (Hynes et al., 1995) and
required for DA neuron development
in vivo (Ferri et al., 2007). Similarly, Kit-
tappa and colleagues noted that foxa2110 Cell Stem Cell 2, February 2008 ª2008was required for the development of ven-
tral midbrain DA and oculomotor neurons
in explant cultures. Moreover, overexpres-
sion of foxa2 in progenitor and embryonic
stem cells, in the presence of Shh, fgf2,
and fgf8, increased the yield of DA neu-
rons in vitro. While a positive feedback
loop has been identified downstream of
Shh and foxa2 (Figure 1), blocking Shh sig-
naling with cyclopramine reduced the ef-
fects of foxa2 by only 50%, suggesting
that foxa2 contributes an Shh-indepen-
dent effect on DA neuron generation.
These in vitro results identify foxa2 ES
cells as an attractive candidate for cell re-
placement, but their in vitro properties re-
main to be tested. Finally, Kittappa and
collaborators also demonstrate that dele-
tion of a single allele of foxa2 results in
a valuable animal model that recapitulates
some of the features of PD. Thus the re-
cent findings from the McKay lab place
foxa2 in the center of the regenerative
medicine stage.
foxa2 at the Crossroads
of Development and Degeneration
The work by Kittappa et al. (2007) has
several important implications for the de-
velopment of cell replacement therapies
for PD (Parish and Arenas, 2007). First,
foxa2 is a strong candidate, in combination
with Shh and FGF8, for the instruction ofElsevier Inc.DA neuron generation. However, foxa2ap-
pears to be more than a developmental
factor, as it maintains survival of adult DA
neurons. These properties may turn out
to be particularly important when grafting
hES-derived DA neurons, which tend to
survive very poorly after transplantation.
Moreover, Shh-induced overgrowth of ES
cell-derived primitive progenitors, which
carry a risk of tumor formation in vivo,
might be avoided by relying instead on
foxa2 to generate DA neurons, as Kittappa
and colleagues observed Shh to be dis-
pensable for late stages in culture. Thus,
foxa2 expression may contribute to cir-
cumvent two of the major roadblocks
facing the use of human ES cells in trans-
plantation settings.
The findings by Kittappa and collabo-
rators may also be applied to assist in
separating DA neurons from non-DA cells
in stem cell preparations. The identifica-
tion of markers and genes that fate map
DA neurons, such as shh (Kittappa et al.,
2007), gli1, and wnt1 (Zervas et al.,
2004), together with the recent identifica-
tion of GLAST+ floor plate radial glia cells
as DA progenitors (Bonilla et al., 2008),
may allow the isolation of DA progenitors.
Similarly, growing knowledge of the
networks that regulate DA neuron devel-
opment (Figure 1 and Prakash and Wurst,
2006) may allow the direct expansion and
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PreviewsFigure 1. Foxa2 Regulates the Specification, Neurogenesis, and Differentiation of DA
Neurons in the Midbrain Floor Plate
Dopaminergic neurons are born in the ventricular zone (VZ) of the midbrain floor plate from proliferative
progenitors, initially Neuroepithelial cells (NE) and subsequently radial glia (RG). They divide asymmetri-
cally to give rise to postmitotic precursors that emerge in the intermediate zone migrating over the
processes of the radial glia, and, in the marginal zone, they differentiate into dopaminergic (DA) neurons.
Two secreted factors, Wnt1 and Shh, regulate two pathways (Shh in red and Wnt1 in blue) that control both
the patterning of the ventral midbrain and the specification of DA neurons in the ventricular zone. Foxa2
regulates the expression of sonic hedgehog (Shh), which in turn activates gli1/2 and foxa2. Foxa2,
Msx1, and Wnt1 regulate directly or indirectly the expression of neurogenin2 (ngn2) and the neurogenic
process by which the progenitors divide to give rise to the DA precursors. foxa2 is also expressed in
DA precursors and neurons, where it regulates the expression of engrailed (En1/2) and nurr1.synchronous differentiation of purified DA
progenitors for therapeutic use.
Other approaches that may move this
application forward include the develop-
ment of drugs that modulate foxa2activity,
target genes, or signaling pathways. Such
compounds could be used to modulate
neural development in stem cell prepara-
tions in vitro and in vivo, to promote neuro-
protection in PD patients, or to promote
regeneration by switching cells from adult
to developmental signaling mode.
foxa2+/ Mice, Welcome
to La Famiglia?
In addition to efforts designed to improve
DA cell production for use in replacement
therapies, it is also essential to develop
animal models that mimic various aspectsof PD. To this end, Kittappa and col-
leagues (2007) reveal that some 18
month-old foxa2+/ mice develop a spon-
taneous and progressive Parkinsonism.
Observed symptoms included alterations
in posture and gait, asymmetric motor be-
havior, and onset of rigidity and tremors.
In addition, symptomatic foxa2+/ animals
exhibit an asymmetric, predominant loss
of substantia nigra DA neurons, bilateral
reactive gliosis, and the appearance of
ubiquitin staining, but no Lewy bodies
were evident.
Oxidative stress, mitochondrial dys-
function, and abnormal accumulation and
phosphorylation of proteins have all been
implicated in the pathogenesis of sporadic
and familial PD. Traditional animal models
depend on neurotoxins to cause oxidativeCell Stem Cdamage and cell death in DA neurons.
These models, unlike PD, are acute and
lack non-nigral pathology or Lewy bodies.
Based on mutations that cause PD, vari-
ous genetic animal models have been
developed that recapitulate some aspects
of its physiopathology, but exhibit little or
no DA cell death. In recent years three
new genetic models that include DA
neuron-restricted cell death phenotypes
have been published. The pitx3-deficient
mice (a deletion of the homeobox gene
pitx3, or the ‘‘aphakia’’ mutant mouse),
and Nurr1+/ animals (with deletion of
one allele of that nuclear receptor) exhibit
impaired survival of mainly substantia ni-
gra DA neurons, and postnatal or adult
motor dysfunction (reviewed in Fleming
et al., 2005). Alternatively, ‘‘Mitomice’’ are
deficient in the mitochondrial transcription
factor A, specifically within DA neurons.
These mice exhibit mutations in mitochon-
drial DNA, oxidative stress, a progressive
loss of nigral and VTA neurons, intraneuro-
nal inclusions, and Parkinsonism with a
time of onset at 14 weeks of age (Ekstrand
et al., 2007).
In comparison to these animal models,
foxa2+/ mice represent a more clinically
relevant system. Specifically, asymmetric
clinical features correlate with severe cell
loss, and with gliosis. The foxa2+/ model
offers more correlative histological find-
ings, affecting substantia nigra, but not
VTA, neurons. However, despite these
similarities, a connection between Foxa2
and human PD has yet to be established.
The identification of foxa2 mutations or
polymorphisms in PD patients would cer-
tainly consolidate the Foxa2 haploinsuffi-
cient mouse as a valid model, providing
a new physiopathological mechanism of
disease.
The absence of any severe pathology
in nonneural organs (pancreas and liver)
or in Foxa2+ neural cell types (motoneu-
rons and oligodendrocytes; Norton et al.,
2005) that are not affected in PD patients
would also aid in validating foxa2+/ mice
as a model of PD. Alternatively, condi-
tional mutants could be generated. In gen-
eral, the strength of the models would in-
crease should other non-DA neurons that
degenerate in PD, such as noradrenergic
neurons of the locus coeruleus (modeled
by the Parkin exon 7 deletion), or serotonin
neurons of the dorsal raphe (regulated by
foxa2; Norton et al., 2005), be impaired.
Compound mutants may be the solution.ell 2, February 2008 ª2008 Elsevier Inc. 111
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provide yet another direct link between
DA neuron development and neurode-
generation. The foxa2+/ mice, together
with the nurr1+/ or pitx3/ animals,
form a growing family of developmental
genes whose deletion affects DA neuron
survival and results in Parkinsonism. The
examination of the precise onset and
kinetics of cell loss, and comparisons of
gene or protein expression at different
stages in these models, may lead to
the identification of novel diagnostic
markers. Moreover, the evaluation of
the impact of additional genetic, epige-
netic, or environmental factors in these
models may contribute to a deeper un-
derstanding of the physiopathology
of PD.112 Cell Stem Cell 2, February 2008 ª2008 EIn sum, the findings reportedbyKittappa
et al. (2007) provide a novel animal model
of Parkinsonism, a novel tool for stem cell
replacement therapy, and a broad array
of possibilities to be explored.
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